Coeptis Therapeutics to Present at the Emerging Growth Conference

Rhea-AI Summary

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that Dave Mehalick, President and CEO, will deliver a virtual presentation at the Emerging Growth Conference on December 6th, 2023. Coeptis is a biopharmaceutical company developing innovative cell therapy platforms for cancer.

WEXFORD, Pa., Dec. 4, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave Mehalick, President and CEO, will deliver a virtual presentation at the Emerging Growth Conference on Wednesday, December 6^th from 1:10-1:40 PM, EST.

Details of the presentation are as follows:

Event:	Emerging Growth Conference
Date & Time:	December 6, 2023, at 1:10 PM, EST
Webcast Registration:	https://gotowebcastscom/startherejsp?ei=1641026&tp_key=4a8f04de2b&sti=coep

 

If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.

About the Emerging Growth Conference 
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner. The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

Cautionary Note Regarding Forward-Looking Statements 
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

CONTACTS

Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
andy.galy@coeptistx.com 

Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
dboateng@tiberend.com

Media
David Schemelia
dschemelia@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-to-present-at-the-emerging-growth-conference-302003876.html

SOURCE Coeptis Therapeutics

FAQ

What is Coeptis Therapeutics Holdings, Inc.'s ticker symbol?

The ticker symbol for Coeptis Therapeutics Holdings, Inc. is COEP.

When will Dave Mehalick deliver the virtual presentation at the Emerging Growth Conference?

Dave Mehalick will deliver the virtual presentation on December 6th, 2023.

What is the focus of Coeptis Therapeutics Holdings, Inc.?

Coeptis is focused on developing innovative cell therapy platforms for cancer treatment.

Where can attendees register for the webcast?

Attendees can register for the webcast at https://gotowebcastscom/startherejsp?ei=1641026&tp_key=4a8f04de2b&sti=coep.

Will the archived webcast be available after the live event?

Yes, the archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.